For MAGED4B, its overexpression has been linked to malignant tumors and poor patient outcome in many types of cancer including breast [28], oral squamous cell carcinoma [29], and hepatocellular carcinoma [30]. Here, MAGED4B is linked to hepatocellular carcinoma.